PAMA and Laboratory Reimbursement: A Market Price Built From an Uneven Sample

PAMA laboratory reimbursement uses private-payer rates and test volumes to set what Medicare pays under the Clinical Laboratory Fee Schedule. That makes the reporting sample part of the price. Hospitals and physician offices supplied little of the data behind the first rates, and repeated delays kept that collection in use for established tests through 2026. For someone inside a laboratory, the question reaches from the private-payer payment file to the tests the business chooses to promote.

The Protecting Access to Medicare Act was supposed to bring Medicare laboratory prices closer to the private market. The first rates cut payment for many routine tests. Taxpayers still paid more as spending shifted toward newer, more expensive tests. For healthcare finance staff, the sample, the payment rate and the test mix each explain a different part of that result.

How the Private-Payer Weighted Median Works

For established tests with reported data, PAMA sets a national payment amount using the private-payer rates laboratories report, weighted by the volume paid at each rate. A rate attached to a large number of tests carries more weight than a rate attached to a small number.

The Centers for Medicare & Medicaid Services payment rule makes both the rate and its matching volume consequential. A report with the right prices but the wrong volumes changes how much influence those prices have. So does leaving a category of laboratories out of the collection. The calculation depends on which transactions reach it.

The rate is national. It receives no geographic adjustment and ordinarily stays in place between reporting cycles. A hospital outreach laboratory and an independent laboratory can face the same Medicare fee-schedule amount even when their private contracts pay differently. The reported private-payer transactions feed a price that Medicare then applies across the country.

Private payer also has a broader meaning here than commercial insurance alone. CMS includes health insurance issuers, group health plans, Medicare Advantage plans and Medicaid managed care organizations. Payments from those managed government programs feed the rate for Medicare’s fee-for-service program.

The input is the final payment rate, including patient cost sharing and reflecting private-payer price concessions. Denied payments and payments made on a capitated basis are excluded. The laboratory’s posted charge, its expected payment and the final rate can tell different stories about the same test. PAMA’s calculation uses the last of those.

Which Laboratories Supply the Data?

A laboratory qualifies to report based on its Medicare billing and revenue. It must meet the laboratory definition under the Clinical Laboratory Improvement Amendments. For ordinary clinical diagnostic laboratory tests, more than 50% of its Medicare revenue must come from the Clinical Laboratory Fee Schedule or Physician Fee Schedule, and it must receive at least $12,500 in fee-schedule revenue during the six-month collection period.

The billing identity matters. Under the original rule, each laboratory qualified under its own National Provider Identifier. The reporting entity submitted the qualifying laboratories’ information under its tax ID. Several laboratories could sit inside that one report.

Hospital outreach needed a separate route. Hospital inpatient and outpatient revenue could overwhelm the laboratory revenue in the eligibility calculation. Under the revision effective in 2019, hospital outreach laboratories could qualify through their Medicare Part B billing on the hospital claim form under bill type 14x. CMS also stopped counting Medicare Advantage revenue against laboratories when deciding whether most of their Medicare revenue came from laboratory and physician fees.

That change has a subtle consequence. Medicare Advantage rates still count as private-payer information for rate setting, even though that revenue no longer counts in the same way when deciding whether a laboratory qualifies to report. The payer’s identity matters at both stages, for different reasons.

The Reporting File Connects a Code, a Rate and a Volume

PAMA’s reporting file contains each test’s billing code, each final private-payer rate and the volume associated with that rate. Where the same test has several paid rates, the rate-volume pairs preserve those differences. Compressing them into a single average would lose the distribution the weighted median needs.

For a billing or finance employee, the useful connection runs from the payer’s final payment to the code, the laboratory component and the volume that reached the submission.

Responsibility reaches the executive level. The president, chief executive or chief financial officer, or an authorized person reporting directly to one of them, certifies that the data are accurate, complete and truthful. That makes the approved submission and the information behind it part of the same account of how the national price was set.

The public cannot inspect those inputs laboratory by laboratory. The rule protects information that would identify a particular payer or laboratory, including its prices and payments. Someone inside the reporting process may see rates or volumes changed between the payment file and the certified submission. Those changes can affect the national price Medicare pays. The public fee schedule would not show who directed them.

The government’s own review found a gap even before the calculation. The Government Accountability Office reported in 2018 that CMS relied on laboratories to decide whether they had to report, did not receive data from every required laboratory and did not estimate how much information was missing. A precise median can still rest on an incomplete collection.

Why Hospital and Physician-Office Representation Matters

Independent laboratories were overrepresented in the first reporting round, while hospital outpatient and physician-office laboratories were underrepresented. The difference mattered because those settings received different private-payer rates for the same tests.

The Medicare Payment Advisory Commission’s June 2021 report measured the gap using Medicare spending. Laboratories that reported represented 85% of independent-laboratory fee-schedule spending, but only 19% of physician-office spending and 3% of hospital-outpatient spending. The hospital business was barely present in the collection used to price its work.

MedPAC then compared private-payer rates for the 100 tests with the highest Medicare laboratory fee-schedule spending in 2016. Hospital outpatient rates averaged 45% more than independent-laboratory rates, and physician-office rates averaged 53% more. Leaving those settings thinly represented changes which prices carry the calculation.

The independent laboratory billing large volumes at negotiated rates has substantial weight in the median. A hospital can perform the same test at a higher private-payer rate and contribute little to the reported distribution. A national rate emerges from the mix of transactions reported, not from giving each laboratory setting an equal say.

MedPAC found that a representative survey could reduce the reporting burden while capturing a broader market. Its analysis also projected higher Medicare spending.

The later hospital-outreach revision addressed eligibility. The repeated reporting delays meant its broader hospital route had not yet changed the 2026 rates for established tests. The definition had changed, but the rates still rested on the earlier collection. That is why the date of the underlying data matters as much as the year printed on the fee schedule.

The 2026 Freeze and the Next Scheduled Rates

In 2026, the law held further phase-in reductions at zero for the year. The reporting window closed on July 31 after opening May 1, using final private-payer payment data from January 1 through June 30, 2025. CMS’s published schedule places the resulting rates in 2027.

The earlier history explains what froze. CMS collected the first private-payer data from January through June 2016, received the reports the following year and began using the new rates in 2018. Reductions were capped at 10% annually during the first three years of implementation. Further phase-in cuts were held at zero from 2021 through 2026, leaving established rates unchanged since 2020.

The next changes remain scheduled. The amended laboratory payment law caps annual reductions at 15% for 2027 through 2029, measured against the preceding year’s payment for the test. After the completed reporting window, the general reporting cycle resumes every three years.

Lower Routine Rates, More Expensive Tests

Medicare laboratory spending rose after the first private-payer rates took effect because spending shifted toward new, high-cost tests. MedPAC found that fee-schedule spending increased from $7.1 billion in 2017 to $7.5 billion in 2019, while overall test utilization remained stable. Lower rates for routine work did not keep the total bill down.

MedPAC found that routine, low-cost tests took larger payment reductions, while some newer, more expensive tests received increases.

For a laboratory’s business, which tests it performs matters alongside how many it performs. A stable total volume can conceal a substantial change in the kinds of tests generating revenue. That is the incentive worth understanding when an insider sees management change the test menu or the services promoted to ordering practices.

New tests can enter the schedule at a price based on comparable tests, charges or resources needed to perform them, while a new advanced diagnostic laboratory test initially receives its actual list charge. That first price can have a different origin from an established test’s weighted median.

For covered clinical laboratory tests billed on assignment, Medicare patients have no deductible or coinsurance. With a national Medicare rate fixed between reporting cycles, the laboratory’s volume and mix of tests become central to the revenue it earns.

The price incentive reaches the ordering office. In Ethical Perspectives on Urine Drug Screening for Pain Physicians, published in Pain Physician in 2014, the paper described how reimbursement could influence the decision to incorporate testing:

That paper predates the first PAMA rates and addresses urine drug screening. It locates the incentive in a concrete decision: whether testing becomes routine in a practice. The corresponding question inside a laboratory is who chose the menu, how it reached the ordering clinician and what patient information supported the tests billed.

The Order and Claim Show the Decision

Our work with laboratory insiders connects those documents to the decisions behind them. A change in the test menu becomes specific when the employee can describe who directed it, what ordering practices received and how the resulting claims compared with the orders. The national spending pattern supplies context. The company’s own instructions and transactions supply the account of its conduct. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Payment File or Test Menu Tells the Story

If you work in laboratory billing, finance or operations and know who changed the reported rates, volumes or tests billed, speak with our whistleblower experts about what you saw. We work beside you to connect the payment data, orders and internal decisions into your strongest laboratory whistleblower case. We bring in laboratory fraud whistleblower lawyers who understand payment reporting and test-selection cases, and stay with you through the process.